Wednesday, March 04, 2015 2:44:18 PM
No study that I'm aware of has ever rated Copax above any of the other drugs. I should have answered your original question a little better. Some (probably most) insurance companies require a patient to fail one or two drugs before they will pay for the newer, more expensive ones. That's a major plus for Copax. Also it has less side effects than say Avonex which is also not as expensive as newer drugs. Neither one is very good, but they are often the starting place.
As for Trimesta being the most efficacious for women, I don't know. I am fairly new to SYN and came because of c. difficile. The MS drug is kind of a bonus (for me) and I need to do more DD on it. I would think it would be a possibility, though.
This is probably common knowledge for the board, and I apologize, but do you know why they chose to do a combo rather than a stand-alone trial?
As for Trimesta being the most efficacious for women, I don't know. I am fairly new to SYN and came because of c. difficile. The MS drug is kind of a bonus (for me) and I need to do more DD on it. I would think it would be a possibility, though.
This is probably common knowledge for the board, and I apologize, but do you know why they chose to do a combo rather than a stand-alone trial?
Recent TOVX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 08:41:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:35:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:45:14 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/20/2026 09:23:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/17/2026 08:15:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 08:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:10:12 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/16/2026 09:32:27 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 12:15:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:10:35 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/04/2026 09:35:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 01:10:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 01:07:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 02:11:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 09:55:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 09:54:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 09:53:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 09:51:09 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/06/2026 08:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2025 01:00:58 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/23/2025 10:04:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2025 10:21:47 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/03/2025 09:00:29 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/03/2025 05:15:04 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/12/2025 09:11:24 PM

